Preferred Name |
ocrelizumab |
|
Synonyms |
PR070769 |
|
ID |
http://purl.bioontology.org/ontology/MESH/C533411 |
|
altLabel |
PR070769 Ocrevus PR-070769 R 1594 R-1594 RG-1594 R1594 PR 070769 |
|
cui |
C5227786 C2605280 C4325109 C1882138 C2605279 |
|
HM |
D061067 |
|
Inverse of RB |
A10SJL62JY 0 |
|
isa | ||
LT |
TRD |
|
Mapped to | ||
MDA |
20081206 |
|
MeSH Frequency |
308 |
|
MMR |
20191031 |
|
notation |
C533411 |
|
PA |
D007155 |
|
PI |
*ANTIBODIES, MONOCLONAL (2008-2011) |
|
prefLabel |
ocrelizumab |
|
SC |
1 |
|
Scope Statement |
a humanized anti-CD20 antibody |
|
SRC |
Curr Opin Investig Drugs 2008 Nov;9(11):1206-15 |
|
TERMUI |
T731255 T731258 T000966339 T731257 T731256 T731254 T731252 T000993862 T731253 |
|
TH |
NLM (2020) NLM (2008) FDA SRS (2017) USAN (19XX) INN (19XX) |
|
tui |
T116 T129 T121 |
Create mapping